Medtronic plc NYSE: MDT is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases an aging population suffers. This assures longevity and a wide moat, which explains how the company has been a dividend aristocrat, having consistently raised its dividend for 47 years.Shares have recently hit 52-week highs but remain a value trading at just 16.46X forward earnings, well below competitors Boston Scientific Co. NYSE: BSX tradi ...

Core Insights - Bridgewater Associates, led by Ray Dalio, has recently invested in three major dividend stocks: ExxonMobil, Medtronic, and Microsoft, indicating a strategic focus on quality dividend-paying companies [1] ExxonMobil - ExxonMobil offers a dividend yield of 3.29% with a conservative payout ratio of 44.9% and has grown its dividend at an annual rate of 2.66% over the past decade [2] - The stock has a 10-year return of 16.5% excluding dividends, which increases to 80.1% when including reinvested dividends, although this still lags behind the S&P 500's total return of 231% [2] - The company is focusing on shareholder concerns by reducing spending, appointing new board members, and setting emission reduction targets, which could enhance cash margins [3] - Risks include potential stranded assets from long-term hydrocarbon projects and lower investment in low-carbon initiatives compared to peers [3] Medtronic - Medtronic has a dividend yield of 3.15% with a high payout ratio of 93.2% and has increased its dividend at a rate of 6.3% annually over the past decade [4] - The stock's 10-year return is 38.3% excluding dividends and 75.7% including reinvested dividends, both trailing the S&P 500 [4] - The company has strong market positions in heart devices, spinal products, and insulin pumps, with a robust pipeline for new treatments [5] - Challenges include increasing competition in the insulin pump market and potential impacts from Medicare reimbursement rates [6] Microsoft - Microsoft offers a lower dividend yield of 0.73% with a payout ratio of 24.8% and has grown its dividend at an impressive rate of 7.6% annually over the past decade [7] - The stock has delivered a remarkable 10-year return of 810% excluding dividends and 965% including reinvested dividends, significantly outperforming the S&P 500 [7] - Growth drivers include a strong position in the public cloud market with Azure and the success of Microsoft 365, which enhances customer willingness to pay for additional features [8] - Risks involve slowing momentum in subscription shifts, a lack of mobile presence, and not being the top player in key growth areas like Azure [8] Investment Consideration - The three stocks—ExxonMobil, Medtronic, and Microsoft—each present unique attributes for income-focused investors, with a commitment to regular dividend payments and strong market positions [9][10]

Company Overview - Medtronic is positioned at an interesting inflection point with new growth drivers contributing to revenue, expecting high single-digit earnings growth later this year [2][7] - The company has shown consistency with seven quarters of mid-single-digit growth, indicating a durable growth trajectory [7] Industry Trends - The MedTech industry is experiencing strong innovation, particularly in areas with significant patient needs such as diabetes and atrial fibrillation (AFib) [5] - Healthy procedure volumes are expected to continue, with a new normal growth rate established post-COVID [9] - Digital advancements, including AI and robotics, are becoming integral to the MedTech industry, enhancing patient outcomes and operational efficiencies [5][16] Market Dynamics - Medtronic is focusing on high-growth markets, particularly in diabetes and hypertension, which are expected to drive future revenue [11][38] - The company is adapting to changes in the Chinese market, where pricing has decreased due to volume-based pricing, but procedure growth remains high [25][26] - Medtronic is localizing its operations in China to mitigate geopolitical risks and enhance market participation [27] Financial Performance - The company has recently seen a slight positive shift in pricing, attributed to a focus on pricing strategies and innovation [30] - Medtronic's revenue from products launched in the last three years accounts for over 20% of current revenue, indicating a strong innovation pipeline [30] Growth Drivers - Key areas of excitement for Medtronic include PFA for AFib ablation and hypertension, which are expected to contribute significantly to growth [11][55] - The company is optimistic about the potential of renal denervation technology, anticipating positive coverage decisions from CMS [68] Strategic Initiatives - Medtronic is committed to enhancing shareholder value through innovation-driven growth and operational efficiencies [36][38] - The company is exploring tuck-in M&A opportunities to bolster its portfolio while maintaining a focus on core operational improvements [49] Robotics and AI - Medtronic is developing its robotics platform, Hugo, with plans for U.S. approval and integration of instruments to enhance its competitive position [75][76] - The company is centralizing its AI initiatives to leverage scale and improve data-driven decision-making across its business segments [21][23]

Medtronic plc (NYSE:MDT) 2024 Wells Fargo Healthcare Conference Summary Company Overview - **Company**: Medtronic plc - **Industry**: Medical Devices - **Participants**: Geoff Martha (Chairman & CEO), Larry Biegelsen (Wells Fargo Medical Device Analyst) Key Points Industry Insights - The MedTech industry is currently experiencing strong innovation, particularly in areas with significant patient needs such as diabetes and atrial fibrillation (AFib) [5][6] - There is a healthy growth rate in procedure volumes globally, with expectations for continued growth [9] - Digital technologies, including AI and robotics, are becoming increasingly integrated into the MedTech industry, enhancing innovation and operational efficiency [5][16] Medtronic's Performance and Strategy - Medtronic is in the early stages of launching new technologies in high-growth areas, showing mid-single-digit growth for seven consecutive quarters [7] - The company anticipates high single-digit earnings growth in the latter half of the fiscal year [7] - Medtronic's revenue is increasingly driven by innovative products launched in the last three years, contributing over 20% to current revenue [30] Market Dynamics - The company has faced challenges in China due to volume-based pricing, but expects to maintain profitability despite lower pricing levels [25][26] - Medtronic is focusing on localizing production in China to mitigate geopolitical risks and enhance market participation [27][28] Pricing and Profitability - Medtronic has seen a slight positive shift in pricing, attributed to a focus on pricing strategies and innovation [29][30] - The company is working to improve gross margins, which have been impacted by inflation and currency fluctuations, with expectations for stabilization in the latter half of the year [42][44] Growth Drivers - Key growth areas include: - **PFA (Pulmonary Vein Ablation)**: Positioned as a leader in the AFib market with a comprehensive product offering [54][55] - **Renal Denervation (Spyral Simplicity)**: Strong clinical outcomes and positive discussions with CMS regarding national coverage decisions [67][68] - **Diabetes Management**: A partnership with Abbott to enhance automated insulin delivery systems, expected to be revenue-accretive [70][72] - **Robotics**: Development of the Hugo robotic platform, with plans for U.S. approval and integration of instruments [74][75] Risks and Challenges - Geopolitical risks, particularly in China, remain a concern, but the company is optimistic about the growth potential in the region [33] - Regulatory risks associated with AI in MedTech, with a need for balanced regulation to foster innovation [35] Future Outlook - Medtronic aims for mid-single-digit organic growth and high-single-digit EPS growth moving forward [46][47] - The company is open to pursuing tuck-in M&A opportunities to enhance growth and shareholder value [48][49] Conclusion - Medtronic is well-positioned to capitalize on innovation and growth in the MedTech industry, with a focus on digital integration, localized production, and strategic partnerships to drive future success [5][7][25][70]

It might not be the most exciting business, but it has other things going its way.Medical device giant Medtronic (MDT 0.44%) has been somewhat of a stock market laggard over the past five years, partly due to pandemic-related disruptions. Even beyond this global issue, the healthcare giant has had trouble growing its revenue and earnings fast enough to excite investors. However, if its latest earnings report is any indication, Medtronic seems to be moving in the right direction, at least within what will ar ...

GALWAY, Ireland, Aug. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the medtech industry and on the company beginning at approximately 11:55 a.m. EDT (12:55 p.m. CDT).A live webcast of the Q&A session will be available on September 4, 2024, by clicking on the Even ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. ...

This MedTech leader is back on track with profitable growth.Medtronic (MDT 0.59%)posted first-quarter earnings (for the period ended on June 30) that exceeded the average of Wall Street estimates. The results were strong enough for the medical technologies giant to raise its full-year profit forecast.Investors should welcome the improved outlook, which could signal the start of a bigger turnaround for the company. Medtronic stock rallied on the report but is still down more than 30% from its record high set ...

WolterkMedtronic (NYSE:MDT) has faced several challenges in the past decade. Some were probably because of poor focus and lack of innovation, while others, like COVID-19, were out of their control. Consequently, the share price has languished after peaking in mid-2021. It currently trades at levels in 2018. However, Medtronic is a market leader with solid competitive advantages. Also, performance has recently improved. The stock is undervalued and possesses a nice yield. I expect the dividend streak to ...

PITTSBURGH, Aug. 23, 2024 /PRNewswire/ -- Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today announced that the Federated Hermes ETF Trust, on behalf of its portfolio, Federated Hermes MDT Large Cap Growth ETF (NYSE: FLCG), which seeks long-term capital appreciation by investing primarily in common stocks of large capitalization (large-cap) U.S. companies with higher forecasted growth values relative to the market, has obtained approval by majority shareholder consent action to c ...